Dr Reddys Laboratories (RDY) Cash & Current Investments (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Cash & Current Investments for 18 consecutive years, with $166.0 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Current Investments fell 7.26% year-over-year to $166.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $166.0 million (down 7.26% YoY) and the FY2026 annual result came in at $166.0 million, down 7.26% from the prior year.
• Cash & Current Investments declined to $166.0 million in Q1 2026 per RDY's latest filing, from $179.0 million in the prior quarter.
• Over the last five years, Cash & Current Investments for RDY reached as high as $776.0 million in Q1 2023 and fell as low as $87.0 million in Q1 2024.
• A 5-year average of $424.3 million and a median of $432.0 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 165.91% — and 2024, when it slumped 88.79%.
• Year by year, Cash & Current Investments stood at $432.0 million in 2022, then jumped by 72.45% to $745.0 million in 2023, then plunged by 88.32% to $87.0 million in 2024, then jumped by 105.75% to $179.0 million in 2025, then decreased by 7.26% to $166.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $166.0 million, $179.0 million, and $87.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.